Sangamo Therapeutics Inc Stock Price, News & Analysis

Sangamo Therapeutics (SGMO) reported Q1 2025 financial results and business updates. Key highlights include a new capsid license agreement with Lilly for CNS disease targets, receiving an $18M upfront fee with potential for $1.4B in additional milestone payments. The company achieved significant milestones in its Fabry disease program, with all patients completing 52-week follow-up required for FDA Accelerated Approval pathway. Q1 2025 financial results showed a net loss of $30.6M ($0.14/share), improved from $49.1M loss in Q1 2024. Revenues increased to $6.4M from $0.5M year-over-year. Cash position stands at $25.2M as of March 31, 2025. The company announced a $23M equity offering and expects current funds to support operations into Q3 2025. Sangamo continues to advance its neurology pipeline, including preparations for Phase 1/2 trials in chronic neuropathic pain and prion disease programs.

Sangamo Therapeutics (SGMO) has announced the pricing of a $23.0 million underwritten offering, consisting of 12,235,000 shares of common stock and pre-funded warrants for 34,398,393 shares, along with accompanying warrants to purchase 46,633,393 shares. The pricing is set at $0.50 per share with accompanying warrant, and $0.49 for each pre-funded warrant with accompanying warrant. The accompanying warrants have an exercise price of $0.75 per share, becoming exercisable after six months and expiring in six years. The offering is expected to close around May 14, 2025. Cantor is serving as the sole book-running manager, and Sangamo plans to use the proceeds for working capital and general corporate purposes.

Sangamo Therapeutics (NASDAQ: SGMO) has announced a change in timing for its first quarter 2025 earnings call. The call has been rescheduled from 4:30 p.m. Eastern to 6:30 p.m. Eastern on Monday, May 12, 2025. The registration and access details remain unchanged, with participants able to join via the same previously provided link.

Attendees are encouraged to join 10 minutes before the start time and can choose between dialing in with a provided number and passcode or using a dial-out option. The webcast will be available through the Investors and Media section of Sangamo's website, with a replay accessible after the call.

Sangamo Therapeutics (NASDAQ: SGMO), a genomic medicine company, has scheduled its first quarter 2025 financial results release for Monday, May 12, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern the same day to discuss financial results and provide business updates.

Participants can register and access the call through a provided link, with a recommendation to join 10 minutes before the start. They can either dial in with a unique passcode or use the dial-out option. A webcast will be available on Sangamo's website in the Investors and Media section, with a replay accessible afterward.

Sangamo Therapeutics (NASDAQ: SGMO) has achieved key milestones for its Fabry disease gene therapy candidate ST-920 (isaralgagene civaparvovec). All patients in the Phase 1/2 STAAR study have completed the FDA-required 52-week follow-up for Accelerated Approval pathway. Preliminary analysis across 32 dosed patients shows continued positive mean eGFR slope, with the therapy being well-tolerated. A productive Type B CMC meeting with the FDA has provided a clear pathway to the planned BLA submission in Q1 2026.

The company expects a pivotal data readout by end of Q2 2025, with potential approval and commercial launch as early as H2 2026. Sangamo is currently in discussions with EMA regarding potential European approval and engaging in business development negotiations for Fabry commercialization.

Sangamo Therapeutics (SGMO) has entered into a license agreement with Eli Lilly for its proprietary neurotropic AAV capsid, STAC-BBB, which demonstrates strong blood-brain barrier penetration capabilities. The agreement includes:

- An $18 million upfront license fee
- Potential earnings of up to $1.4 billion in additional fees and milestone payments across five possible disease targets
- Tiered royalties on potential net sales

Lilly receives worldwide exclusive rights to use STAC-BBB for one initial target, with the option to add four additional targets for treating central nervous system diseases. This marks Sangamo's third agreement since announcing STAC-BBB in March 2024. Sangamo will handle the technology transfer, while Lilly will be responsible for research, development, manufacturing, and commercialization of resulting gene therapy products.

Sangamo Therapeutics (NASDAQ: SGMO) reported key developments and financial results for Q4 and full year 2024. The company secured two significant neurology license agreements: a global epigenetic regulation and capsid delivery agreement with Genentech and a capsid license agreement with Astellas, raising over $100M in non-dilutive funding.

Key highlights include: FDA clearance for ST-503 IND for treating intractable pain, with patient enrollment expected mid-2025; successful nonclinical proof of concept in prion disease; and alignment with FDA on Accelerated Approval pathway for isaralgagene civaparvovec in Fabry disease.

Financial results show Q4 2024 net loss of $23.4M ($0.11/share) compared to $60.3M loss in Q4 2023. Full-year 2024 net loss was $97.9M versus $257.8M in 2023. Q4 revenues were $7.6M, up from $2.0M in Q4 2023. Cash position stood at $41.9M as of December 31, 2024.

Sangamo Therapeutics (SGMO) has scheduled its fourth quarter and full year 2024 financial results release for Monday, March 17, 2025, after market close. The company will host an earnings conference call at 4:30 p.m. Eastern on the same day.

Additionally, Sangamo announced its participation in the Barclays 27th Annual Global Healthcare Conference in Miami, Florida, from March 11-13, 2025. CEO Sandy Macrae will present on Wednesday, March 12 at 12:00 p.m. Eastern. Both the earnings call and conference presentation will be accessible via webcast, with replays available afterward.